By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AdkhabarAdkhabarAdkhabar
Notification Show More
Font ResizerAa
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Reading: Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Share
Font ResizerAa
AdkhabarAdkhabar
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Search
  • Home
  • Automobile
  • Entertainment
  • Esports
  • Food
  • Health
  • Life Style
  • News
  • Technology
  • Travel
Follow US
Adkhabar > Blog > Health > Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Health

Sanuwave to Participate in the 44th Annual J.P. Morgan Healthcare Conference

GlobeNews Wire
Last updated: 10/12/2025 4:37 PM
GlobeNews Wire
Published: 10/12/2025
Share
SHARE

EDEN PRAIRIE, Minn., Dec. 10, 2025 (GLOBE NEWSWIRE) — Sanuwave Health, Inc. (the “Company” or “Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved next-generation wound care products, is pleased to announce that it will be attending the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA from January 12th to January 15th 2026.

Those wishing to meet with company management during the conference should reach out to investors@sanuwave.com to schedule a time.

About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, and plans for future business development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement, except as may be required by applicable law.

Contact: investors@sanuwave.com 

Texan Artisinal Review: Context, Accuracy & Risk in NYC of Bisnow’s Real-Estate Reporting
InSolare Energy Wins 600 MW / 1,200 MWh BESS Project from SECI — One of the Largest Standalone Awards to Date, Strengthening Its Leadership in Net Zero Infrastructure
Award-Winning Film An Inconvenient Study Sparks Global Debate on Vaccine Safety and Chronic Disease
Lingnan University in Hong Kong debuts in THE World University Rankings: Comes 47th globally in International Outlook
Gold, Glamour, and Grit: IDeA the World College at D-Arc
TAGGED:44thannualconferencehealthcarej.p.morganNasdaq:SNWVnewsparticipatesanuwavetheUS80303D3052
Share This Article
Facebook Email Print
- Advertisement -

Follow US

Find US on Social Medias
FacebookLike
XFollow
YoutubeSubscribe

Weekly Newsletter

Subscribe to our newsletter to get our newest articles instantly!
Popular News
Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
News

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

23/10/2025
Bybit Kazakhstan and Bank CenterCredit Launch Direct Fiat Channel to Boost Local Crypto Accessibility
Hexaware Deepens Google Cloud Partnership with the Launch of Advanced Insurance Solutions
Altri to Acquire a Majority Stake in AeoniQ to Scale World’s First Industrial Production of Climate Positive Textile Yarn
Driving Digital India Wirelessly: AVA Brings Smart Collaboration to InfoComm India 2025
- Advertisement -
- Advertisement -
- Advertisement -

Categories

  • Automobile
  • Entertainment
  • E-Sports
  • Food
  • Health
  • Technology
  • LifeStyle
  • Travel

About Us

Through our news networks, we raise millions of users' awareness. We are among the world's most reputable news networks.
Quick Link
Top Categories
  • Entertainment

Subscribe US

Subscribe to our newsletter to get our newest articles instantly!

AdkhabarAdkhabar
Copyright © 2021 - 2025 AdKhabar. All Rights Reserved. POWERED BY Life Care News.
Join Us!
Subscribe to our newsletter and never miss our latest news, podcasts etc..
Zero spam, Unsubscribe at any time.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?